Bone School 2025 Application

Candidate profile:

Clinical paediatric adult and endocrine trainees and fellows with an interest in bone disease

Clinical and translational researchers

The Bone School aims to deliver high-profile teaching of an advanced working knowledge and skills related to bone metabolism, bone imaging, bone fragility, and skeletal disorders. Therefore, the course is best suited to the following groups:

Senior (Year3+) Trainees in paediatric or adult endocrinology or related specialities (genetics/ metabolic/orthopaedics/internal medicine/paediatrics)
Clinical fellows with an interest in bone disease
Postdoctoral clinical and translational researchers in fields related to bone metabolism or skeletal disorders
Numbers will be limited to 48 delegates in order to promote interaction and discussion both within and outside the lecture theatre. Participants will have the opportunity to learn from and interact with some of leading experts in the field.

Candidates should fulfill the following requirements:

Very good level of spoken English
Solid experience in the paediatric bone field (at least 3-5 years of residency)
Published in the paediatric bone field (first author international publications)
Having a strong intent to be further trained in this topic
Willing to interact with colleagues during and after the course to disseminate their experience
Successful applicants will be requested to send a case for presentation during the course – more information about this will be sent after registration.

All applicants must be a member of ISCBH, if you are not already and your application is successful, we will invite you to become a member.
Successful applicants will then purchase their registration package and accommodation. The registration package will include all meals and refreshments throughout the course at Les Pensieres, Annecy, France as well as access to the two and a half day course and all course materials. Applicants will need to book their own travel and should arrive in time for the start of the course (08:30 on Wednesday 28 May 2025).

Registered Office: Kaiser Josef Straße 9, 6020 Innsbruck, Austria

Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our Rare Disease division is focused on generating scientific and technological breakthroughs for people living with a rare disease via the discovery and development of integrated therapeutic solutions and novel indications of established medicines in rare and ultra-rare blood, endocrine and renal disorders. Novo Nordisk employs about 50,800 people in 80 countries out of which 3.300 within rare disease.

Kyowa Kirin strives to create and deliver novel medicines with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company with a heritage of 70+ years, we apply cutting-edge science including an expertise in antibody research and engineering, to address the needs of patients and society across multiple therapeutic areas including Nephrology, Oncology, Immunology/Allergy and Neurology. Across four regions – Japan, Asia Pacific, North America and EMEA/International – we focus on our purpose, to make people smile, and are united by our shared values of commitment to life, teamwork/Wa*, innovation and integrity.

*Harmony and loop among people.

Founded in 2007, Ascendis Pharma is applying its innovative TransCon™ technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients’ lives. Guided by our core values of patients, science and passion, we use our TransCon technologies to fulfill our mission of developing new and potentially best-in-class therapies that address unmet medical needs. Ascendis is headquartered in Copenhagen, Denmark, and has additional facilities in Europe and the United States.

Inozyme Pharma is a rare disease biopharmaceutical company developing novel therapeutics for the treatment of diseases driven by pathologic mineralization and intimal proliferation which impact the vasculature, soft tissue and skeleton. We are initially focused on developing an enzyme therapy to treat ENPP1 and ABCC6 Deficiencies, rare genetic diseases associated with significant morbidity, mortality, and unmet medical need.

BioMarin is a world leader in developing and commercializing innovative therapies for rare diseases driven by genetic causes. With a 20-year history, BioMarin remains steadfast to its original mission—to bring new treatments to market that will make a big impact on small patient populations. These conditions are often inherited, difficult to diagnose, progressively debilitating, have few, if any, treatment options, and are usually ignored. Visit www.biomarin.com to learn more.

Alexion, AstraZeneca Rare Disease, is the group within AstraZeneca focused on rare diseases, created following the 2021 acquisition of Alexion Pharmaceuticals, Inc. As a leader in rare diseases for 30 years, Alexion is focused on serving patients and families affected by rare diseases and devastating conditions through the discovery, development and commercialization of life-changing medicines. Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Headquartered in Boston, Massachusetts, Alexion has offices around the globe and serves patients in more than 50 countries.

Apply now

Application Form